Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 16;142(1):106–118. doi: 10.1182/blood.2022018475

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Figure 2. — Deletion of Fgf23 in osteocytes reduces circulating FGF23 in acute inflammation. Serum (A) cFGF23, (B) iFGF23, (C) i/cFGF23, (D) phosphate, (E) 1,25OH₂D, bone (F) Fgf23 mRNA, and (G) FGF23 protein expression in 6-week-old WT and Fgf23^Dmp1-cKO mice 6 hours after administration of a single dose of 250 ng/g IL-1β. n ≥ 5 per group, P < .05 vs (a) WT Ctr, (b) Fgf23^Dmp1-cKO Ctr (c) WT IL-1β. (H) Fgf23 mRNA levels and secreted (I) cFGF23 and (J) iFGF23 in primary osteoblast cultures cultured for 3 weeks in osteoblastic medium and treated with saline or 10 ng/mL of IL-1β for 6 hours. n ≥ 3 per group, P < .05 vs (a) WT Ctr, (b) Fgf23^Dmp1-cKO Ctr (c) WT IL-1β.